Genentech, Inc. Patent applications |
Patent application number | Title | Published |
20160137742 | HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided. | 05-19-2016 |
20160136295 | BIOMARKERS FOR TREATMENT WITH ANTI-TUBULIN CHEMOTHERAPEUTIC COMPOUNDS - Provided herein are biomarkers for predicting sensitivity to treating cancer with anti-tubulin chemotherapeutic agents. | 05-19-2016 |
20160130624 | HARVEST OPERATIONS FOR RECOMBINANT PROTEINS - The present invention contemplates a method of producing a recombinant protein comprising (a) fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, and (b) harvesting said recombinant protein under conditions where dO | 05-12-2016 |
20160130358 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES - Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. | 05-12-2016 |
20160122316 | SERINE/THREONINE KINASE INHIBITORS - Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 05-05-2016 |
20160108113 | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND METHODS OF USE - The present invention relates to anti-alpha-synuclein (anti-α-synuclein) antibodies and methods of using the same. | 04-21-2016 |
20160102146 | ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES - The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same. | 04-14-2016 |
20160102119 | INHIBITORS OF IAP - Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: | 04-14-2016 |
20160097098 | METHODS AND COMPOSITIONS FOR DETECTING AUTOIMMUNE DISORDERS - The invention provides methods and compositions useful for detecting autoimmune disorders. | 04-07-2016 |
20160096893 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES - The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same. | 04-07-2016 |
20160096850 | ALKYNYL ALCOHOLS AND METHODS OF USE - The invention relates to compounds of Formula (0): | 04-07-2016 |
20160090378 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 03-31-2016 |
20160090377 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 03-31-2016 |
20160082120 | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES - Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents. | 03-24-2016 |
20160075787 | ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES - The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same. | 03-17-2016 |
20160074529 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES - The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same. | 03-17-2016 |
20160074528 | ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS - The invention provides antibody-drug conjugates comprising an antibody conjugated to an anthracycline drug moiety via a disulfide linker, anthracycline disulfide intermediates, and methods of using the antibody-drug conjugates. | 03-17-2016 |
20160069895 | IMMUNOGENIC MUTANT PEPTIDE SCREENING PLATFORM - The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions. | 03-10-2016 |
20160068607 | THERAPEUTIC PROTEIN FORMULATIONS - The present invention generally concerns formulations having a pH that inhibits aspartyl isomerization at an Asp-Asp motif in a therapeutic protein contained in such a formulation. | 03-10-2016 |
20160060353 | ANTI-HER2 ANTIBODY VARIANTS - The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains | 03-03-2016 |
20160060262 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof - The invention provides novel compounds having the general formula: | 03-03-2016 |
20160052940 | BIHETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R | 02-25-2016 |
20160051550 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE - The invention provides A combination of, a) a compound of Formula Ia: | 02-25-2016 |
20160046608 | C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses - The present invention provides for pyrimidine compounds of Formula I-I and embodiments thereof | 02-18-2016 |
20160045515 | MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER - Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents. | 02-18-2016 |
20160039770 | CRYSTALLINE FORMS OF AN ESTROGEN RECEPTOR MODULATOR - Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the estrogen receptor modulator (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid. Also described are pharmaceutical compositions suitable for administration to a mammal that include the estrogen receptor modulator, and methods of using the estrogen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with estrogen receptor activity. | 02-11-2016 |
20160032013 | RON COMPOSITIONS AND METHODS OF USE THEREOF - This invention relates to RON compositions, in particular RON composition comprising a RON agonist, and methods of using the compositions for the treatment of diseases. The invention also relates to diagnosis of RON-associated or MSP-associated diseases. | 02-04-2016 |
20160024504 | TREATING TH2-MEDIATED DISEASES BY INHIBITION OF BROMODOMAINS - The invention provides methods for treating Th2 cytokine-mediated diseases by inhibiting bromodomain function. | 01-28-2016 |
20160024217 | PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA - The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture. | 01-28-2016 |
20160024089 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS - A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R | 01-28-2016 |
20160017052 | Anti-Factor D Antibody Variants and Uses Thereof - The invention relates to anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. | 01-21-2016 |
20160016948 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS - This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer. | 01-21-2016 |
20160002593 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION - Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided. | 01-07-2016 |
20160002266 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES - Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds. | 01-07-2016 |
20160002228 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS - The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. | 01-07-2016 |
20160002121 | METHODS AND COMPOSITIONS FOR RADIOHALOGEN PROTEIN LABELING - Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [ | 01-07-2016 |
20160000910 | Monoclonal Antibody - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). | 01-07-2016 |
20150376570 | METHODS AND COMPOSITIONS FOR PRODUCING INDUCED HEPATOCYTES - The present invention relates to methods and compositions for use in generating induced hepatocytes by reprogramming non-hepatocyte cells. | 12-31-2015 |
20150376283 | FGFR1 AGONISTS AND METHODS OF USE - The invention provides FGFR1 agonists, including agonistic anti-FGFR1 antibodies, and methods of using the same. | 12-31-2015 |
20150376272 | INHIBITION OF ANGIOGENESIS IN REFRACTORY TUMORS - The present invention relates generally to the inhibition of tumor angiogenesis. In particular, the invention concerns the prevention or treatment of tumor angiogenesis and the suppression of tumor growth in tumors refractory to an anti-vascular endothelial growth factor (VEGF) treatment, using IL-17 antagonists, such as anti-IL-17 antibodies and other antagonists. | 12-31-2015 |
20150376265 | ANTIBODY COMPOSITIONS AND METHODS OF USE - The invention provides compositions comprising anti-gH antibodies and anti-Complex I antibodies as well as methods of using the same. | 12-31-2015 |
20150368358 | KLOTHO BETA - The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4. | 12-24-2015 |
20150368244 | DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 12-24-2015 |
20150366985 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES - The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same. | 12-24-2015 |
20150361392 | LIQUID CULTURING OF EPITHELIAL STEM CELLS - Provided herein is a method of culturing epithelial stem cells and tissue fragments comprising epithelial stem cells in liquid cultures. | 12-17-2015 |
20150361184 | METHODS OF MODULATING DLK STABILITY - The invention provides for methods of decreasing dual leucine zipper kinase (DLK) stability in a neuron, or decreasing or inhibiting the phosphorylation of certain amino acid residues of DLK, comprising administering to a neuron, or portion thereof, an agent which decreases or inhibits the phosphorylation of DLK and decreases the stability of DLK as well as methods for inhibiting or preventing neuronal degeneration in a patient by administering to a patient an agent which inhibits phosphorylation of dual leucine zipper kinase (DLK). | 12-17-2015 |
20150344888 | USP30 INHIBITORS AND METHODS OF USE - Inhibitors of USP30 and methods of using inhibitors of USP30 are provided. In some embodiments, methods of treating conditions involving mitochondrial defects are provided. | 12-03-2015 |
20150337269 | METHODS FOR INACTIVATION OF VIRUSES AND BACTERIA IN CELL CULTURE MEDIA - The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized. | 11-26-2015 |
20150336962 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein. | 11-26-2015 |
20150335650 | METHODS OF TREATING PR-POSITIVE, LUMINAL A BREAST CANCER WITH PI3K INHIBITOR, PICTILISIB - Methods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent. | 11-26-2015 |
20150329636 | LOW AFFINITY BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES AND USES THEREFOR - The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same. | 11-19-2015 |
20150328195 | 1,7-DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 11-19-2015 |
20150322153 | ANTI-PD-L1 ANTIBODIES AND ARTICLES OF MANUFACTURE - The present application relates to anti-PD-L1 antibodies, which have therapeutic use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity. | 11-12-2015 |
20150322136 | BINDING POLYPEPTIDES WITH OPTIMIZED SCAFFOLDS - The invention provides variant heavy chain variable domains (VH) with increased folding stability. Libraries comprising a plurality of these polypeptides are also provided. In addition, compositions and methods of generating and using these polypeptides and libraries are provided. | 11-12-2015 |
20150322002 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF - The invention provides novel compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X | 11-12-2015 |
20150320859 | METHODS OF TREATING CANCER USING PD-L1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS - The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. | 11-12-2015 |
20150314016 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 11-05-2015 |
20150307888 | COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY - The invention provides compositions and methods for regulating intracellular osmolarity in cells, e.g., in cultured cells, including in cultured cells in bioreactors. The invention provides nucleic acids comprising at least one osmo-responsive transcriptional regulatory element (OR-TRE), and cells, vectors, products of manufacture, artificial organs or implants and the like containing an osmo-responsive transcriptional regulatory element (OR-TRE). | 10-29-2015 |
20150307617 | ANTI-OX40 ANTIBODIES AND METHODS OF USE - The invention provides anti-OX40 antibodies and methods of using the same. | 10-29-2015 |
20150307611 | METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE - Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease. | 10-29-2015 |
20150290196 | EGFR MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment. | 10-15-2015 |
20150285771 | IONIC STRENGTH-MEDIATED PH GRADIENT ION EXCHANGE CHROMATOGRAPHY - The present invention provides methods for analyzing compositions of polypeptides such as antibodies by ionic strength-mediated pH gradient ion exchange chromatography. In some aspects, the methods use a combination of pH gradients and ionic strength gradients to separate the polypeptide from charge variants of the polypeptide. In some aspects, the methods use a stable ionic strength to optimize the pH gradient separation window to separate the polypeptide from charge variants. Such methods are useful for analyzing polypeptide, e.g. antibodies, with a pI greater than 9 or a pI less than 7. In some aspects, the invention provides a multiproduct method for the analysis of polypeptides of varying pI's. | 10-08-2015 |
20150284458 | ANTIBODY VARIANTS - Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen. | 10-08-2015 |
20150274812 | ANTI-INFLUENZA B VIRUS HEMAGGLUTININ ANTIBODIES AND METHODS OF USE - The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same. | 10-01-2015 |
20150273059 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS - The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab. | 10-01-2015 |
20150266953 | IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF - The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 09-24-2015 |
20150259400 | ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE - The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same. | 09-17-2015 |
20150258099 | METHODS AND COMPOSITIONS FOR MODULATING ESTROGEN RECEPTOR MUTANTS - Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. | 09-17-2015 |
20150258080 | THERAPEUTIC COMBINATIONS WITH ESTROGEN RECEPTOR MODULATORS - Described herein are therapeutic combinations with estrogen receptor modulators for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 09-17-2015 |
20150246963 | METHODS OF TREATING ALZHEIMER'S DISEASE - Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided. | 09-03-2015 |
20150246124 | ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF BREAST CANCER - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human subjects susceptible to or diagnosed with breast cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 09-03-2015 |
20150232551 | ANTIBODIES DIRECTED TO IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES OF THEREOF - The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 08-20-2015 |
20150225760 | HARVEST OPERATIONS FOR RECOMBINANT PROTEINS - The present invention contemplates methods of producing a recombinant protein comprising fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, harvesting said recombinant protein under conditions where dO | 08-13-2015 |
20150224071 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF - The invention provides novel compounds having the general formula: | 08-13-2015 |
20150218276 | ANTIBODIES AND METHODS OF USE - The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB. | 08-06-2015 |
20150218176 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I wherein R | 08-06-2015 |
20150210971 | METHOD OF CULTURING EUKARYOTIC CELLS - An apparatus and method to maintain pH within a range conducive for cell growth in a bicarbonate-containing cell culture system without the addition of base. The method relies on the gas transfer characteristics of the bioreactor system to modulate the CO | 07-30-2015 |
20150210772 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND AN ANTI-CD20 ANTIBODY - The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an anti-CD20 antibody and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. | 07-30-2015 |
20150197814 | EGFR AND KRAS MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and KRAS and methods of detecting such mutations as well as prognostic methods for identifying tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein and/or a mutated KRAS gene or mutated KRAS protein in a tumor sample. | 07-16-2015 |
20150197560 | HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR - The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies. | 07-16-2015 |
20150197529 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS - Compounds of the formula I: | 07-16-2015 |
20150197509 | SUBSTITUTED SULFONAMIDE SOLUTIONS - The invention is concerned with the compounds of formula (I): | 07-16-2015 |
20150196642 | ANTIBODY FORMULATIONS - The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab). | 07-16-2015 |
20150191487 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS - Compounds of the formula I: | 07-09-2015 |
20150190514 | STABILIZING POLYPEPTIDES WHICH HAVE BEEN EXPOSED TO UREA - Methods for stabilizing polypeptides, such as anti-HER2 antibodies, which have been exposed to urea. | 07-09-2015 |
20150190506 | COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND PD-1 AXIS BINDING ANTAGONISTS - The invention provides compositions and methods for treating cancers. The method comprises administering a PD-1 axis binding antagonist and an OX40 binding agonist. | 07-09-2015 |
20150182537 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I wherein R | 07-02-2015 |
20150175619 | SUBSTITUTED PYRAZOLES AND USES THEREOF - The present invention provides for compounds of formula 0 and various embodiments thereof, and compositions comprising compounds of formula 0 and various embodiments thereof. | 06-25-2015 |
20150158952 | CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES - Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: | 06-11-2015 |
20150158851 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Provided herein are compounds of formula (AA): | 06-11-2015 |
20150158846 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY - Heteroaryl pyridone and aza-pyridone amide compounds with electrophilic functionality of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 06-11-2015 |
20150152117 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS - A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R | 06-04-2015 |
20150150970 | GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN ErbB ANTAGONIST CANCER THERAPY - The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody. | 06-04-2015 |
20150148585 | COMBINATION THERAPY FOR THE TREATMENT OF GLIOBLASTOMA - This invention concerns methods of treating a patient diagnosed with glioblastoma comprising administering to said patient a therapy comprising an effective amount of an anti-VEGF antibody and a chemotherapeutic. | 05-28-2015 |
20150148559 | PROCESS FOR MAKING AMINO ACID COMPOUNDS - The invention provides new processes for making and purifying amino acid compounds, which are useful in the preparation of AKT inhibitors used in the treatment of diseases such as cancer, including the compound (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one. | 05-28-2015 |
20150147333 | ANTI-RSPO ANTIBODIES AND METHODS OF USE - Provided herein are anti-RSPO antibodies, in particular anti-RSPO2 antibodies and/or anti-RSPO3 antibodies, and methods of using the same. | 05-28-2015 |
20150141283 | IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF - The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 05-21-2015 |
20150133638 | SINGLE-CHAIN ANTIBODIES AND OTHER HETEROMULTIMERS - The invention provides engineered heteromultimeric protein complexes constructed using one, two, or three tethers and methods for making, using, and purifying such complexes, such as antibodies with different binding properties. | 05-14-2015 |
20150132309 | KLOTHO BETA - The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4. | 05-14-2015 |
20150126491 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS - Compounds of the formula I: | 05-07-2015 |
20150126448 | METHODS AND COMPOSITIONS FOR MODULATING HGF/MET - The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF β chain to c-met. | 05-07-2015 |
20150111879 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING - The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: | 04-23-2015 |
20150111869 | USE OF A COMBINATION OF A MEK INHIBITOR AND AN ERK INHIBITOR FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES - The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and an ERK inhibitor (such as GDC-0994). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer. | 04-23-2015 |
20150111211 | PREDICTING RESPONSE TO A HER INHIBITOR - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. | 04-23-2015 |
20150110816 | METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES - The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates. | 04-23-2015 |
20150110791 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE - The present invention relates to anti-transferrin receptor antibodies and methods of their use. | 04-23-2015 |
20150105550 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING - The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: | 04-16-2015 |
20150105429 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS - Compounds of the formula I: | 04-16-2015 |
20150098946 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule encoding a full-length TAT polypeptide having an amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein. | 04-09-2015 |
20150094302 | ALKYLATED PIPERAZINE COMPOUNDS - Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating cancer mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of cancer in mammalian cells, or associated pathological conditions, are disclosed. | 04-02-2015 |
20150093381 | FIXED DOSING OF HER ANTIBODIES - The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab. | 04-02-2015 |
20150093375 | METHODS FOR INHIBITING OCULAR ANGIOGENESIS - The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders. | 04-02-2015 |
20150087664 | QUINAZOLINE COMPOUNDS AS SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula (I) wherein R | 03-26-2015 |
20150087630 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER - Methods of use of compounds of formula (I) for treating cancer: | 03-26-2015 |
20150086568 | ANTI-VEGF ANTIBODIES - The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies. | 03-26-2015 |
20150086545 | COMBINATION THERAPY OF HER EXPRESSING TUMORS - The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors. | 03-26-2015 |
20150086543 | DIAGNOTIC MARKERS - The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene. | 03-26-2015 |
20150086537 | HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided. | 03-26-2015 |
20150080367 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF - The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof. | 03-19-2015 |
20150079081 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE - Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. | 03-19-2015 |
20150072918 | PROTEIN PURIFICATION - A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants. | 03-12-2015 |
20150071924 | Anti-Angiogenesis Therapy for the Treatment of Previously Treated Breast Cancer - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, in combination with one or more additional anti-tumor therapeutic agents in previously treated metastatic breast cancer. | 03-12-2015 |
20150071910 | BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS - Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto. | 03-12-2015 |
20150065781 | COMBINATION THERAPY FOR THE TREATMENT OF GLIOBLASTOMA - This invention concerns methods of treating a patient diagnosed with glioblastoma comprising administering to said patient a therapy comprising an effective amount of an anti-VEGF antibody and a chemotherapeutic. | 03-05-2015 |
20150065482 | ALKYNYL ALCOHOLS AND METHODS OF USE - The invention relates to compounds of Formula (0): | 03-05-2015 |
20150065388 | ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES - The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same. | 03-05-2015 |
20150064191 | ANTI-C-MET-ANTIBODY FORMULATIONS - Provided herein are pharmaceutical formulations comprising a one-armed, anti-c-met antibody and uses of the same. | 03-05-2015 |
20150064186 | METHODS OF TREATING LIVER CONDITIONS USING NOTCH2 ANTAGONISTS - Methods and compositions for the treatment of liver conditions are provided, such methods and compositions comprising Notch2 antagonists, e.g., anti-Notch2 antibodies. Liver conditions include, but are not limited to, chronic liver disease. | 03-05-2015 |
20150064178 | DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA - The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods. | 03-05-2015 |
20150064171 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAEPTUC AGENTS, AND METHODS OF USE - The invention provides combinations comprising a) compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R | 03-05-2015 |
20150057260 | ALKYNYL ALCOHOLS AND METHODS OF USE - The invention relates to compounds of Formula (0): | 02-26-2015 |
20150056196 | ANTIBODY PURIFICATION BY CATION EXCHANGE CHROMATOGRAPHY - A method for purifying an antibody by cation exchange chromatography is described in which a high pH wash step is used to remove of contaminants prior to eluting the desired antibody using an elution buffer with increased conductivity. | 02-26-2015 |
20150056190 | DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER - The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods. | 02-26-2015 |
20150056132 | IMMUNO-PET IMAGING OF ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR - Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of detecting or determining the presence of STEAP-1 proteins are provided. | 02-26-2015 |
20150051380 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS - The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors. | 02-19-2015 |
20150051238 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS - Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease. | 02-19-2015 |
20150051201 | BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS - Compounds of formula I: | 02-19-2015 |
20150050275 | PURIFICATION OF ANTI-C-MET ANTIBODIES - Provided herein are methods of purifying anti-c-met antibodies, compositions and pharmaceutical formulations comprising purified anti-c-met antibodies, and methods of using the same. | 02-19-2015 |
20150044205 | COMPOSITIONS AND METHOD FOR TREATING COMPLIMENT-ASSOCIATED CONDITIONS - The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive biomarkers. | 02-12-2015 |
20150044198 | REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS - The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations. | 02-12-2015 |
20150038460 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor - The invention relates to novel compounds of Formula I: | 02-05-2015 |
20150037332 | TREATMENT OF METASTIC BREAST CANCER - The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel. | 02-05-2015 |
20150037319 | METHOD FOR PREPARING A COMPOSITION COMPRISING HIGHLY CONCENTRATED ANTIBODIES BY ULTRAFILTRATION - The present invention provides a method for preparing a composition comprising highly concentrated antibodies by ultrafiltration in batch concentration mode having a first constant feed rate step and a second controlled feed rate step. | 02-05-2015 |
20150031674 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I wherein R | 01-29-2015 |
20150023951 | ANTI-VEGF ANTIBODIES - Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. | 01-22-2015 |
20150023871 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 01-22-2015 |
20150017188 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES - Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: | 01-15-2015 |
20150011461 | HETEROARYL PYRIDONE AND AZA-PYRIDONE AMIDE COMPOUNDS - Heteroaryl pyridone and aza-pyridone amide compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 01-08-2015 |
20150010558 | COMPOSITIONS AND METHODS FOR TREATING COAGULATION RELATED DISORDERS - Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (TF) to form a complex in which factor X or factor IX binding to the complex is inhibited and the administration is sufficient to prevent or treat the sepsis in the mammal. The invention has a wide spectrum of useful applications including treating sepsis, disorders related to sepsis, and inflammatory diseases such as arthritis. | 01-08-2015 |
20150010540 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD22 ANTIBODY-DRUG CONJUGATE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD22 antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD22 antibody-drug conjugate. | 01-08-2015 |
20150010537 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS - Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided. | 01-08-2015 |
20140378449 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS - A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R | 12-25-2014 |
20140377276 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS - The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization. | 12-25-2014 |
20140377257 | COMBINATION THERAPY FOR B CELL DISORDERS - The invention provides methods of treating B cell based malignancies and B-cell regulated autoimmune disorders using a combination therapy of anti-CD20 antibody with a BLyS antagonist. | 12-25-2014 |
20140371429 | METHODS AND COMPOSITION FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES - The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof. | 12-18-2014 |
20140370003 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF - The present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process for preparing highly concentrated antibody compositions, and highly concentrated antibody products. | 12-18-2014 |
20140363873 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 12-11-2014 |
20140363439 | ANTI-LRP6 ANTIBODIES - The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms. | 12-11-2014 |
20140363438 | NEUREGULIN ANTIBODIES AND USES THEREOF - The invention provides anti-neuregulin1 antibodies and methods of using the antibodies in treating diseases or disorders, such as cancer. In a particular embodiment, the anti-neuregulin1 antibodies bind to both neuregulin1α and neuregulin 1β isoforms. | 12-11-2014 |
20140363435 | KLOTHO BETA - The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4. | 12-11-2014 |
20140363432 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF - The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided. | 12-11-2014 |
20140363431 | METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS - The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use. | 12-11-2014 |
20140356376 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES - The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same. | 12-04-2014 |
20140356375 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES - The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same. | 12-04-2014 |
20140356352 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate. | 12-04-2014 |
20140348855 | ANTIBODY FORMULATIONS - Formulations comprising an anti-IL-13 antibody are provided, including pharmaceutical formulations and methods of using such formulations. | 11-27-2014 |
20140343036 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES - The invention provides novel compounds having the general formula: | 11-20-2014 |
20140342404 | POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION - The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof. | 11-20-2014 |
20140341916 | THERAPEUTIC COMBINATIONS AND METHODS OF TREATING MELANOMA - The invention provides therapeutic combinations of anti-ETBR antibodies and MAP kinase inhibitors and methods of using the same to treat melanoma. | 11-20-2014 |
20140341902 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS - The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. | 11-20-2014 |
20140341893 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. The present invention also provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels in patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. | 11-20-2014 |
20140341887 | METHODS FOR TREATING, DIAGNOSING, AND MONITORING RHEUMATOID ARTHRITIS - Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents. | 11-20-2014 |
20140341886 | TREATMENT WITH ANTI ErbB2 ANTIBODIES - The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient. | 11-20-2014 |
20140336361 | ASSEMBLY OF BISPECIFIC ANTIBODIES - Described herein are methods for the efficient production of a heteromultimeric protein, such as a bispecific antibody. Heteromultimeric proteins may be capable of specifically binding to more than one target molecule or different epitopes on a single target molecule. The methods modulate parameters to improve assembly of the heteromultimeric proteins at higher yield and efficiency than otherwise possible. Also described are compositions comprising a hinge-containing polypeptide, such as a half-antibody. | 11-13-2014 |
20140335107 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 11-13-2014 |
20140335078 | Use Of Complement Inhibitors To Treat Ocular Diseases - The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5, C6, C7, C8, C9, or C5b-9. | 11-13-2014 |
20140328940 | MODULATION OF AXON DEGENERATION - The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons. | 11-06-2014 |
20140328849 | ANTI-CRTH2 ANTIBODIES AND METHODS OF USE - The invention provides anti-CRTh2 antibodies and methods of using the same. | 11-06-2014 |
20140328805 | BIHETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R | 11-06-2014 |
20140323706 | NUCLEIC ACIDS ENCODING RECEPTOR FOR IL-17 HOMOLOGOUS POLYPEPTIDES AND USES THEREOF - The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 10-30-2014 |
20140323477 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I, or a pharmaceutically acceptable salt thereof, wherein R | 10-30-2014 |
20140322756 | METHOD FOR MAKING MULTISPECIFIC ANTIBODIES HAVING HETEROMULTIMERIC AND COMMON COMPONENTS - The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers. | 10-30-2014 |
20140322221 | MULTIVALENT ANTIBODIES AND USES THEREFOR - The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies. | 10-30-2014 |
20140322203 | FORMULATIONS WITH REDUCED OXIDATION - The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation. | 10-30-2014 |
20140322202 | TREATMENT WITH ANTI ErbB2 ANTIBODIES - The present invention concerns the treatment of cancer with anti-ErbB2 antibodies. | 10-30-2014 |
20140322129 | ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES - The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same. | 10-30-2014 |
20140314794 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same. | 10-23-2014 |
20140314782 | ANTI-NOTCH2 NRR ANTIBODIES - The invention provides anti-Notch antibodies, and in particular, antibodies that bind Notch2 NRR, and methods of using the same. | 10-23-2014 |
20140314779 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION - Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided. | 10-23-2014 |
20140314778 | FORMULATIONS WITH REDUCED OXIDATION - The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation. | 10-23-2014 |
20140314763 | CROSS-REACTIVE AND BISPECIFIC ANTI-IL-17A/F ANTIBODIES - The present invention relates generally to antibodies cross-reactive with IL-17A and IL-17F, and bispecific anti-IL-17A/F and their uses. | 10-23-2014 |
20140314749 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF HEPATIC CANCERS - The present invention relates to methods of treating liver cancer using a Notch signaling inhibitor. Compositions and methods for the treatment of liver cancers are also provided. | 10-23-2014 |
20140314748 | ANTIBODY FORMULATIONS - The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations. | 10-23-2014 |
20140314747 | PREDICTING RESPONSE TO EGFR INHIBITORS - Methods of predicting whether a cancer will respond to an EGFR inhibitor are provided. | 10-23-2014 |
20140314711 | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE - The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof. | 10-23-2014 |
20140309403 | NOVEL PROTEIN PURIFICATION METHODS - The invention provides methods of reducing fouling of ultrafiltration membranes in processes wherein virus particles are removed from aqueous solutions comprising virus particles and at least one protein by adding a surfactant or non-surfactant, non-ionic agent to the aqueous solution prior to filtration. The invention also provides methods to dissociate protein aggregates or to reduce the formation of protein aggregates by adding a surfactant or non-surfactant, non-ionic agent to the protein solution. | 10-16-2014 |
20140309210 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - A compound of formula I: | 10-16-2014 |
20140308277 | PERTUZUMAB VARIANTS AND EVALUATION THEREOF - The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof. | 10-16-2014 |
20140308273 | CELL CULTURE MEDIA AND METHODS OF ANTIBODY PRODUCTION - Cell culture media are provided herein as are methods of using the media for cell culture and antibody production from cells. Compositions comprising antibodies and fragments thereof, produced by the methods herein are also provided. | 10-16-2014 |
20140308270 | METHOD AND FORMULATION FOR REDUCING AGGREGATION OF A MACROMOLECULE UNDER PHYSIOLOGICAL CONDITIONS - The invention provides a method for reducing aggregation and inhibiting flocculation of a macromolecule, such as a protein, under physiological conditions, by the addition of 5% to 20% polyvinylpyrrolidone (PVP) with a molecular weight range of 2000 to 54,000 daltons. The invention further provides a method to minimize inflammation at the injection site during subcutaneous administration of a macromolecule. In further aspects, the invention provides pharmaceutical formulations for subcutaneous administration of a macromolecule, and methods of treating a CD20 positive cancer or an autoimmune disease, comprising administering a humanized anti-CD20 antibody in a pharmaceutical formulation of the invention. The invention further provides an in vitro dialysis method to evaluate the ability of an excipient to reduce aggregation of an antibody or other macromolecule under physiological conditions. | 10-16-2014 |